BioSpace News Archive

Today, The Association for Frontotemporal Degeneration (AFTD) and Target ALS announced a groundbreaking partnership and call for proposals to identify treatments and biomarkers for FTD and ALS

The Green Park Collaborative (GPC), a major initiative of the Center for Medical Technology Policy (CMTP), is partnering with Allergy & Asthma Network (AAN), to develop a core set of outcomes to be used in pivotal and late phase clinical trials of therapies for moderate to severe asthma

Horizon Eye Specialists & Lasik Center, the leading comprehensive eye care center in Arizona, announces it has started offering the latest generation in multifocal implants, the AcrySof IQ PanOptix lens by Alcon.

SpendEdge, a leading provider of procurement market intelligence solutions, has announced the completion of their latest success story on achieving cost savings of $15 million for a Canadian medical device company.

Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced that a study published in the Journal of Clinical Microbiology reports a potential new diagnostic, mChip-Ld, which can be performed in 15 minutes in a physician’s office, offers efficacy improvement over the current gold standard diagnostic, the two-tier test, and may be able to identify a patient’s Lyme disease stage.

A comfortable and in-home remedy to tackle lower leg and feet pain while improving muscle endurance. [15-October-2019] HOLLYWOOD, Fla. , Oct. 15, 2019 /PRNewswire/ -- Beurer, the number one leading health care brand in Europe , lands in North America and introduces an EMS device that focuses on relieving muscle tension, promoting blood flow and boosting lower leg a

Ichnos (‘īk-nōz) Sciences officially opened its doors to the world today as an independent, fully integrated, global biotech company

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the first patient has been dosed in a Phase 2b clinical trial of PB2452,

Kleo Pharmaceuticals Inc. announced that its CEO Doug Manion, M.D., FRCP, will present at the 2019 BIO Investor Forum, which will be held at the Westin St. Francis Union Square in San Francisco on October 22-23rd.

Heska Corporation, a provider of advanced veterinary diagnostic and specialty products, plans to report its third quarter 2019 financial performance in a press release on Tuesday, November 5, 2019 before the market opens, and to host an earnings call to discuss the results at 9 a.m. MT / 11 a.m. ET on the same day..